Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06751238 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
A Phase 1 study of Juvenile Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT06751238 is a Phase 1 study of Juvenile Psoriatic Arthritis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT06751238, a Phase 1 study of Juvenile Psoriatic Arthritis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
Conditions Studied
Interventions
- BIOLOGICAL Secukinumab
Study Locations (7)
Ohio
- Cincinnati Childrens Hospital - Cincinnati
- Univ Hosp Cleveland Medical Center - Cleveland
Florida
- University of Florida - Gainesville
Illinois
- Ann and Robert H Lurie Childs Hosp - Chicago
North Carolina
- Levine Childrens Hospital - Charlotte
Oregon
- Legacy Emanuel Research Hosp Portland - Portland
Texas
- Texas Arthritis Center - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-09-24 |
| Est. Completion | 2032-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06751238
The ClinicalTrials.gov registry entry for NCT06751238 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Juvenile Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Secukinumab is the first listed.
NCT06751238 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Ohio, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06751238 about?
NCT06751238 is a clinical study titled "Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).". The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
What is the current status of trial NCT06751238?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-09-24. Estimated completion is 2032-12-01.
What conditions does trial NCT06751238 study?
This clinical trial studies the following conditions: Juvenile Psoriatic Arthritis.
What interventions are being tested in trial NCT06751238?
The interventions under investigation include: Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06751238?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06751238 being conducted?
This trial has 7 study locations across Florida, Illinois, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.